XSHE
002524
Market cap312mUSD
Oct 09, Last price
4.16CNY
1D
2.46%
1Q
10.05%
Jan 2017
-60.90%
IPO
-50.76%
Name
Guangzheng Eye Hospital Group Co Ltd
Chart & performance
P/E
—
P/S
2.42
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.05%
Rev. gr., 5y
-3.26%
Revenues
885m
-0.86%
Net income
-19m
L-88.84%
CFO
125m
+80.57%
Dividend
May 28, 20130.025 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Guangzheng Eye Hospital Group Co., Ltd. provides various ophthalmic medical services in China. It operates through Steel Structure Segment; Energy Segment; and Medical and Health segment. The steel structure segment engaged in steel structure processing and sales and installation business. The energy segment involved in gas station leasing, oil and natural gas sales, and home installation business. The medical and health segment provides ophthalmic medical services. it offers diagnosis and treatment of various eye diseases; medical optometry services; invests in, operates, and manages eye hospitals; and provides related services. In addition, it engages in leasing of houses; and property and consulting services. The company formerly known as Guangzheng Group Co., Ltd. Guangzheng Eye Hospital Group Co., Ltd. was founded in 2001 and is headquartered in Xinjiang, China.
Key people
Qi Wang
Chief Financial Officer · since 2025
Helian Zhou
Executive Vice President · since 2025
Shaowei Chen
Vice President, Director · since 2025
Zhifang Chen
Vice President · since 2025
Lin Liu
Vice President · since 2025
Ao Rong
Vice President · since 2025
Yonghui Zhang
Vice President · since 2025
Meixin Zhou
Vice President, Director · since 2025
Yonglin Zhou
Chairman of the Board, President · since 2025
Xin Feng
Director · since 2018
Junying Li
Secretary of the Board, Director, Chief Economist · since 2025
Yong Wang
Director · since 2008
Dongsheng Wang
Independent Director · since 2025
Independent Director · since 2021
Independent Director · since 2008
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||